Literature DB >> 9665898

Disease activity and risk of lymphoma in patients with rheumatoid arthritis: nested case-control study.

E Baecklund1, A Ekbom, P Sparén, N Feltelius, L Klareskog.   

Abstract

Entities:  

Mesh：

Year:  1998        PMID： 9665898      PMCID： PMC28610          DOI： 10.1136/bmj.317.7152.180

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  5 in total

1.  Cancer morbidity in rheumatoid arthritis.

Authors:  P Prior; D P Symmons; C F Hawkins; D L Scott; R Brown
Journal:  Ann Rheum Dis       Date:  1984-04       Impact factor: 19.103

2.  Incidence of cancer among patients with rheumatoid arthritis.

Authors:  G Gridley; J K McLaughlin; A Ekbom; L Klareskog; H O Adami; D G Hacker; R Hoover; J F Fraumeni
Journal:  J Natl Cancer Inst       Date:  1993-02-17       Impact factor: 13.506

3.  Lymphoproliferative cancer and other malignancy in patients with rheumatoid arthritis treated with azathioprine: a 20 year follow up study.

Authors:  A J Silman; J Petrie; B Hazleman; S J Evans
Journal:  Ann Rheum Dis       Date:  1988-12       Impact factor: 19.103

4.  Neoplasms of the immune system in rheumatoid arthritis.

Authors:  D P Symmons
Journal:  Am J Med       Date:  1985-01-21       Impact factor: 4.965

5.  Mortality from cancer in patients with rheumatoid arthritis.

Authors:  R Myllykangas-Luosujärvi; K Aho; H Isomäki
Journal:  Scand J Rheumatol       Date:  1995       Impact factor: 3.641
  5 in total
  72 in total

Review 1.  Updated consensus statement on biological agents for the treatment of rheumatoid arthritis and other immune mediated inflammatory diseases (May 2003).

Authors:  D E Furst; F C Breedveld; J R Kalden; J S Smolen; G R Burmester; M Dougados; P Emery; A Gibofsky; A F Kavanaugh; E C Keystone; L Klareskog; A S Russell; L B A van de Putte; M H Weisman; A F Kavenaugh
Journal:  Ann Rheum Dis       Date:  2003-11       Impact factor: 19.103

Review 2.  Advances in targeted therapy: safety of biological agents.

Authors:  E C Keystone
Journal:  Ann Rheum Dis       Date:  2003-11       Impact factor: 19.103

3.  Long term safety of etanercept in elderly subjects with rheumatic diseases.

Authors:  R Fleischmann; S W Baumgartner; M H Weisman; T Liu; B White; P Peloso
Journal:  Ann Rheum Dis       Date:  2005-09-08       Impact factor: 19.103

4.  Safety of extended treatment with anakinra in patients with rheumatoid arthritis.

Authors:  R M Fleischmann; J Tesser; M H Schiff; J Schechtman; G-R Burmester; R Bennett; D Modafferi; L Zhou; D Bell; B Appleton
Journal:  Ann Rheum Dis       Date:  2006-01-05       Impact factor: 19.103

Review 5.  The British Society for Rheumatology biologics register.

Authors:  K Watson; D Symmons; I Griffiths; A Silman
Journal:  Ann Rheum Dis       Date:  2005-11       Impact factor: 19.103

Review 6.  Swedish registers to examine drug safety and clinical issues in RA.

Authors:  J Askling; C M Fored; P Geborek; L T H Jacobsson; R van Vollenhoven; N Feltelius; S Lindblad; L Klareskog
Journal:  Ann Rheum Dis       Date:  2006-01-13       Impact factor: 19.103

7.  Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2006.

Authors:  D E Furst; F C Breedveld; J R Kalden; J S Smolen; G R Burmester; P Emery; E C Keystone; M H Schiff; P L C M van Riel; M E Weinblatt; M H Weisman
Journal:  Ann Rheum Dis       Date:  2006-11       Impact factor: 19.103

8.  Safety analyses of adalimumab (HUMIRA) in global clinical trials and US postmarketing surveillance of patients with rheumatoid arthritis.

Authors:  M H Schiff; G R Burmester; J D Kent; A L Pangan; H Kupper; S B Fitzpatrick; C Donovan
Journal:  Ann Rheum Dis       Date:  2006-01-26       Impact factor: 19.103

Review 9.  Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007.

Authors:  D E Furst; F C Breedveld; J R Kalden; J S Smolen; G R Burmester; J Sieper; P Emery; E C Keystone; M H Schiff; P Mease; P L C M van Riel; R Fleischmann; M H Weisman; M E Weinblatt
Journal:  Ann Rheum Dis       Date:  2007-11       Impact factor: 19.103

10.  Risk of lymphoma: inflammatory bowel disease and immunomodulators.

Authors:  Y S Ang; R J Farrell
Journal:  Gut       Date:  2006-04       Impact factor: 23.059
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.